SCHEMBL2161036

SCHEMBL2161036

O/N=C\c1cccc2cccnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.52
▸ GAA P10253 3/20 0.52
▸ NPC1 O15118 2/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ MAPT P10636 5/20 0.51
▸ L3MBTL1 Q9Y468 4/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ TDP1 Q9NUW8 3/20 0.51
▸ MITF O75030 1/20 0.51
▸ AGTR1 P30556 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ MMP2 P08253 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ CHRM1 P11229 1/20 0.50
▸ COMT P21964 1/20 0.50
▸ ADRA1A P35348 1/20 0.50
▸ METAP2 P50579 1/20 0.50
▸ METAP1 P53582 1/20 0.50
▸ HDAC8 Q9BY41 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2161037 1.00 KDM4E (0.52) KDM4EGAANPC1RAB9AMAPT
SCHEMBL30114981 0.81 KDM4E (0.49) KDM4EGAANPC1RAB9AMAPT
SCHEMBL30114982 0.81 KDM4E (0.49) KDM4EGAANPC1RAB9AMAPT
SCHEMBL30114987 0.81 KDM4E (0.49) KDM4EGAANPC1RAB9AMAPT
SCHEMBL7749257 0.78 CCR1 (0.53) KDM4EGAANPC1RAB9AMAPT
SCHEMBL7749251 0.78 CCR1 (0.53) KDM4EGAANPC1RAB9AMAPT
SCHEMBL28282372 0.78 KDM4E (0.54) KDM4EGAANPC1RAB9AMAPT
SCHEMBL28137987 0.77 ALOX12 (0.39) KDM4EGAANPC1RAB9AMAPT
SCHEMBL28261089 0.77 KDM4E (0.46) KDM4EGAANPC1RAB9AMAPT
Hydrogen Sulfide SCHEMBL28261078 0.76 KDM4E (0.45) KDM4EGAANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366704-B1 Inhibitors of serine proteases VERTEX PHARMA (US) 2013-10-23 — — EP disclosed
EP-2631238-A1 Spirocyclic inhibitors of serine proteases for the treatment of hcv infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-28 — — EP disclosed
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 — — US disclosed
EP-1917269-B1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMA (US) 2011-10-26 — — EP disclosed
EP-2366704-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-21 — — EP disclosed
EP-2364984-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-14 — — EP disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 — — US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 — — US disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 KDM4E 2603/4885GAA 773/4885NPC1 252/4885
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 KDM4E 1669/4885GAA 771/4885NPC1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback